Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd., has received FDA approval for the clinical trial application of its selective small molecule FGFR2/3 inhibitor ABSK061 for treating children with achondroplasia (ACH) [1] Group 1 - The FDA has granted permission for the IND of ABSK061, which is a significant milestone for the company [1] - The approval is complemented by the previously awarded Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) by the FDA, which will facilitate the overseas clinical development of ABSK061 [1]

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase following the approval of its clinical trial application for the innovative treatment product SM17 for inflammatory bowel disease (IBD) by the National Medical Products Administration (NMPA) of China [1] Group 1: Company Developments - The IND approval for SM17 marks a critical milestone as it expands the treatment scope from atopic dermatitis (AD) to IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC), addressing significant unmet medical needs [1] - The company has completed follow-up for the Phase I bridging study involving healthy volunteers for the subcutaneous injection formulation of SM17, with data to support the advancement of IBD indications into Phase II clinical development [1] - In parallel with advancing the IND, the company is completing a bridging study transitioning SM17 from intravenous to subcutaneous injection, expected to be completed by the first quarter of this year [1] Group 2: Future Plans - The company anticipates initiating Phase II clinical trials for AD as early as the second quarter of this year [1] - The expansion of SM17's indications from AD to IBD is viewed as a significant opportunity to address unmet medical needs in a clinically and commercially valuable area [1]

Core Viewpoint - The company has successfully completed the review period for the new drug clinical trial application for CBT-199, a potential best-in-class ophthalmic candidate, and is authorized to proceed with Phase 2 clinical trials [1][2]. Group 1: Clinical Trial Progress - The company's wholly-owned subsidiary, ADS Therapeutics LLC, registered in Delaware, USA, has had its clinical trial application for CBT-199 accepted by the FDA without any suspension orders [1]. - CBT-199 is a novel topical ophthalmic emulsion designed to treat presbyopia, a common age-related condition that affects the ability to focus on near objects [1]. - The clinical trial for CBT-199 is now recognized as safe to advance, marking a significant milestone in its clinical development [2]. Group 2: Product Details - CBT-199 utilizes the company's proprietary non-aqueous platform formulation, which includes a parasympathomimetic miotic agent to induce pupil constriction, thereby improving near vision through a pinhole effect [1]. - The formulation is designed to prevent the degradation of active ingredients over time, enhancing drug stability, and features a consumer-friendly multi-dose bottle design for prolonged shelf life and a comfortable medication experience [1]. Group 3: Future Developments - The drug discovery process for CBT-199 commenced in China in 2023, with preclinical animal studies evaluating safety and tolerability starting in June 2023 [2]. - The company will continue to monitor the review progress closely and will provide updates to shareholders and potential investors regarding the latest developments in its business [2].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has announced the acceptance of its new drug clinical trial application for JSKN033, a combination therapy for advanced cervical cancer, by the National Medical Products Administration (NMPA) [1] Group 1: Clinical Trial Details - JSKN033 is a high-concentration subcutaneous compound formulation consisting of a bispecific antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) and a programmed death ligand 1 (PDL1) immune checkpoint inhibitor [1] - The clinical trial, identified as JSKN033-202, is an open-label, multicenter, Phase II study aimed at evaluating the safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics of JSKN033 in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with advanced cervical cancer [1] - All participants will receive treatment with JSKN033 in combination with either cisplatin or carboplatin, and the choice of platinum drug and the inclusion of bevacizumab will be determined by the researchers based on individual patient circumstances [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has announced the acceptance of its new drug clinical trial application for JSKN033, a combination therapy for advanced cervical cancer, by the National Medical Products Administration (NMPA) [1] Group 1: Clinical Trial Details - JSKN033 is a high-concentration subcutaneous compound formulation consisting of a bispecific antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) and a programmed death ligand 1 (PDL1) immune checkpoint inhibitor [1] - The clinical trial, identified as JSKN033-202, is an open-label, multicenter, Phase II study aimed at evaluating the safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics of JSKN033 in combination with platinum-based chemotherapy, with or without bevacizumab, for treating patients with advanced cervical cancer [1] - All participants will receive treatment with JSKN033 in combination with either cisplatin or carboplatin, and the choice of platinum drug and the inclusion of bevacizumab will be determined by the researchers based on individual patient circumstances [1]

Core Viewpoint - Deutsche Bank reiterated its "Hold" rating on Neurocrine Biosciences (NBIX.US) and maintained a target price of $152, believing that investor expectations for the clinical results were low, thus the impact on the stock price will be minimal [1] Group 1: Clinical Trial Results - Neurocrine Biosciences reported that the Phase III KINECT-DCP trial for valbenazine (Ingrezza) in treating Dystonic Cerebral Palsy (DCP) failed, eliminating the opportunity for Ingrezza to expand its indications beyond tardive dyskinesia (TD) and Huntington's disease (HD) [1] - The failure of the DCP indication for Ingrezza was not included in Deutsche Bank's valuation model, meaning it will not alter the company's valuation [1] Group 2: Sales Estimates and Market Focus - Deutsche Bank estimates the peak sales for Ingrezza to be approximately $2.821 billion, compared to consensus expectations of about $2.998 billion, which includes around $2.585 billion from TD sales and approximately $236 million from HD sales [2] - In the absence of label expansion, Deutsche Bank expects management to focus on increasing Ingrezza prescriptions, supported by an expanded sales team, while the TD market is anticipated to grow despite currently low penetration [2]

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) in China for the clinical trial (IND) application of its oral, highly active, and selective small molecule KRAS G12D inhibitor, ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The clinical trial application for ABSK141 has been approved by the NMPA [1] - ABSK141 is designed to target advanced solid tumors with the KRAS G12D mutation [1] - The drug is characterized as an oral, highly active, and highly selective small molecule inhibitor [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) in China for its new drug clinical trial application for the oral, highly active, and selective small molecule KRAS G12D inhibitor ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The subsidiary involved is Shanghai Heyu Biopharmaceutical Technology Co., Ltd. [1] - The drug ABSK141 targets a specific mutation (KRAS G12D) associated with advanced solid tumors [1] - The approval marks a significant step in the development of targeted therapies for cancer treatment [1]

Core Viewpoint - The company has completed the enrollment for the Phase III clinical trial AFFIRM-205, evaluating the combination therapy of LAE002 (afuresertib) and fulvestrant for treating HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN gene alterations [1] Group 1 - The Phase III clinical trial AFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled study aimed at assessing the antitumor efficacy and safety of the combination therapy [1] - The company aims to announce the top-line data from this critical Phase III study in the first half of 2026 [1] - A new drug application will be submitted to the National Medical Products Administration of China later in 2026 [1] Group 2 - The company has signed an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. on November 12, 2025 [1] - Under the licensing agreement, Qilu Pharmaceutical has obtained exclusive rights for the research, development, and commercialization of LAE002 (afuresertib) in the Chinese region, including mainland China, Hong Kong, Macau, and Taiwan [1]

Core Viewpoint - The company has completed the enrollment for the Phase III clinical trial AFFIRM-205, evaluating the efficacy and safety of LAE 002 (afuresertib) in combination with Fulvestrant for treating HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN gene alterations [1] Group 1 - The Phase III clinical trial AFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled study [1] - The company aims to announce the topline data from this key Phase III study in the first half of 2026 [1] - A new drug application will be submitted to the National Medical Products Administration of China later in 2026 [1] Group 2 - The company has signed an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. on November 12, 2025 [1] - Under the licensing agreement, Qilu Pharmaceutical has obtained exclusive rights for research, development, and commercialization of LAE 002 (afuresertib) in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan [1]